OPG-W2-2
The cell line is not validated yet.
URi006-A
General
iPSC Line |
|
| hPSCreg name | URi006-A |
| Cite as: | URi006-A |
| Alternative name(s) |
OPG-W2-2
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 1st July 2026 |
| User feedback | |
Provider |
|
| Generator | University of the Ryukyus (UR) |
| Derivation country | Japan |
External iPSC Databases |
|
| BioSamples | SAMEA122972230 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46,XX
Karyotyping method:
G-Banding
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | 琉球大学 |
| Approval number | 714 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
iPSC Derivation
General |
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions
| Medium |
Other medium:
Base medium: StemFit AK02N (Ajinomoto)
Main protein source: Serum concentration: % |
iPSC Characterisation
Analysis of undifferentiated iPSCs
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46,XX
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.